Project description
AHR: pro or con cancer?
The aryl hydrocarbon receptor (AHR) is a transcription factor that controls key biological processes and becomes activated by the binding of a ligand. Its role in antitumour immunity seems to be context dependent, demonstrating both promoting and suppressive effects. This questions its suitability as an anticancer drug target and necessitates further investigation into its mechanism of action. Funded by the European Research Council, the CancAHR project will investigate the downstream effects of AHR activation and delineate its implication in cancer. Results will have clinical projections as they may be used to stratify cancer patients and design specific therapeutic interventions.
Objective
The aryl hydrocarbon receptor (AHR) is a critical regulator of tumor progression by modulating both tumor cell intrinsic malignant properties as well as anti-tumor immunity. However, depending on the context, the AHR can exert either tumor-promoting or tumor-suppressive effects, thus limiting its potential as a drug target. To exploit the AHR for cancer therapy a comprehensive understanding of its activation and biological outcomes is necessary. The opposing effects of the AHR in cancer likely stem from the complexity of its activation and biological functions, which are cell type-, ligand-, and context-specific. Moreover, recent results from our laboratory suggest that nutritional stress conditions also affect AHR activity. The detection of AHR activation in tissues mainly relies on the quantitation of AHR target gene expression. However, until recently, the context specificity of AHR target gene expression had impeded systematic investigation of AHR activity across human cancers. Our team has developed a pan-tissue AHR signature that detects AHR activity irrespective of cell type or ligand, and enables the analysis of the biological functions mediated through AHR activation. The combination of the AHR signature with iterative cycles of computational biology analyses and laboratory experimentation puts us in a unique position to investigate AHR activation and its downstream effects. CancAHR will hence systematically delineate how the AHR is activated in cancer, why AHR activation is cell type-specific, and which AHR downstream mediators drive clinical outcomes. The identification of the molecular mechanisms underlying the diverse outcomes of AHR activation in cancer will enable (i) the identification of patients, in which AHR activation contributes to clinical outcome; (ii) the development of clinical interventions tailored to the specific mechanisms of AHR activation; and (iii) stratification of patients to precision therapies modulating AHR activity.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences chemical sciences organic chemistry hydrocarbons
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC - HORIZON ERC Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2021-COG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
69120 Heidelberg
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.